Granules India is currently trading at Rs. 163.30, up by 7.35 points or 4.71% from its previous closing of Rs. 155.95 on the BSE.
The scrip opened at Rs. 156.85 and has touched a high and low of Rs. 163.55 and Rs. 154.70 respectively. So far 6937 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 188.85 on 19-Feb-2020 and a 52 week low of Rs. 84.25 on 26-Jul-2019.
Last one week high and low of the scrip stood at Rs. 164.20 and Rs. 138.05 respectively. The current market cap of the company is Rs. 3964.99 crore.
The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 20.95% and 36.14% respectively.
Granules India has received EU GMP approval for its Unit-V, high potent API and Finished Formulations manufacturing facility located at Visakhapatnam, Andhra Pradesh, India. This approval is valid for three years. This facility was audited in the month of January 2020 for good manufacturing practices of API and Oral solid dosage.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1826.10 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1488.15 |
Lupin | 2251.80 |
Zydus Lifesciences | 1009.40 |
View more.. |